Mankind Pharma and Innovent Biologics Partner to Launch Groundbreaking PD-1 Immunotherapy in India

Duchenne Muscular Dystrophy: Diagnosis, Treatment, and Emerging Therapies

Ikena Oncology and Inmagene Biopharmaceuticals Announce Merger to Form ImageneBio

Fujirebio and Eisai Partner to Advance Diagnostics for Neurodegenerative Diseases

European Commission Approves Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H or dMMR mCRC

Deerfield Management to Acquire Singular Genomics for $20 Per Share in All-Cash Deal

EU Approval of Tagrisso Sets New Standard for EGFR-Mutated NSCLC Treatment

Aurobindo Pharma’s Subsidiary CuraTeQ Secures UK Approval for Bevacizumab Biosimilar

SCG Cell Therapy Partners with A*STAR BTI and NATi to Advance RNA-Based Therapeutics

Korea's National Bio Big Data Project: Advancing Precision Medicine with Macrogen and Illumina

GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

Home
/
update
/
details

Advanced Genomics APAC and Compass Bioinformatics Forge Strategic Alliance to Enhance Rare Disease and Cancer Diagnostics in APAC Region

NextEdge Admin

31 Oct 2024

2 min 38 sec

Compass Bioinformatics,Rare Disease,Cancer Diagnostics

Advanced Genomics APAC has announced a strategic partnership with Compass Bioinformatics Inc., aiming to broaden the use of next-generation sequencing (NGS) technology for rare disease and cancer diagnostics across Japan, South Korea, Southeast Asia, and Australasia. This collaboration is set to drive market expansion and improve access to precision medicine across the APAC region.

Focusing on rare disease diagnostics, the partnership will integrate Advanced Genomics APAC's Cell3™ Target: Nexome Panel, designed for effective pathogenic variant capture, with Compass Bioinformatics' InheriNext® analytical software. Together, they provide a complete, streamlined diagnostic solution that spans from library preparation to high-precision data analysis, allowing for faster, more accurate diagnoses. The InheriNext® platform, which launched in 2020, has already facilitated over 3,500 rare disease diagnoses and received notable regulatory clearances, including U.S. FDA Class I Medical Device approval, Taiwan TFDA QMS certification, and ISO 13485 standards compliance.

This partnership is poised to significantly impact patients with rare diseases, who often face diagnostic delays of over six years, with genetic factors accounting for over 80% of cases. The collaboration’s combined technologies aim to reduce these delays, enhancing diagnostic efficiency across APAC healthcare institutions.

Andy Chang, General Manager of Advanced Genomics APAC, highlighted the partnership's potential to embed Nexome into APAC’s diagnostic landscape, with anticipated benefits for rare disease and cancer patients. Ping-Cheng Hsiung, General Manager of Compass Bioinformatics, emphasized their shared mission to advance genomic diagnostics, increasing both accuracy and efficiency. In the coming months, the partners plan to launch services and share results with healthcare providers across the region, contributing to advancements in diagnostics for rare diseases and oncology.